IDEXX Lifts Full-Year Outlook as Diagnostics Demand Offsets 1.8% Drop in Vet Visits; Shares Jump 19%
IDXX sits 32% above its 52-week low of $500.61.
Summary
IDEXX beat on Q3 and raised full-year profit and revenue guidance, and the stock is up more than 19% in morning trading. Revenue rose 10% to $1.21 billion against a $1.19 billion consensus, with EPS up 18% to $4.01. The pitch is that diagnostics intensity, not clinic traffic, carries growth: US same-store clinical visits fell an estimated 1.8% in the quarter, yet recurring diagnostics revenue in companion animal grew 9.6% in the US on higher testing frequency and uptake of the InVue Dx analyzer and CancerDx dog cancer screen. Management was explicit that innovation and commercial execution are doing the work, not a visit rebound. This follows the Q3 release furnished in today's 8-K and the earlier wire report on the beat; the guidance raise and the size of the share move are the new information. Watch whether the raised bar holds if vet visit declines persist into Q4.
At the time of this announcement, IDXX was trading at $659.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.9B. The 52-week trading range was $500.61 to $769.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.